Researchers developed a Mutation-Annotated Prognostic Score (MAPS) for intrahepatic cholangiocarcinoma (ICC) after resection, integrating TP53 and KRASG12 mutations with clinical parameters. The MAPS model, validated internally and externally, demonstrated superior predictive efficacy (c-indices 0.782 and 0.731, respectively) compared to existing models. It effectively identified ICC patients’ overall survival and showed promise in predicting benefits from upfront surgery and adjuvant therapy, providing a valuable tool for personalized prognostication and treatment decision-making.
Journal Article by Wang XY, Zhu WW (…) Qin LX et 14 al. in Int J Surg
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.